Relx (LON:REL) Rating Lowered to Hold at Berenberg Bank
Relx (LON:REL) was downgraded by research analysts at Berenberg Bank to a “hold” rating in a research report issued to clients and investors on Friday, ThisIsMoney.Co.Uk reports. They currently have a GBX 2,100 ($27.62) target price on the stock, down from their prior target price of GBX 2,120 ($27.89). Berenberg Bank’s price objective would indicate a potential upside of 1.45% from the stock’s current price.
Other equities analysts have also issued research reports about the stock. Liberum Capital reiterated a “buy” rating on shares of Relx in a report on Thursday. HSBC reiterated a “buy” rating on shares of Relx in a report on Monday, January 13th. Citigroup upgraded shares of Relx to a “buy” rating in a report on Tuesday, January 21st. Morgan Stanley lifted their price target on shares of Relx from GBX 1,830 ($24.07) to GBX 2,250 ($29.60) and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Finally, UBS Group reiterated a “sell” rating on shares of Relx in a report on Friday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. Relx presently has a consensus rating of “Hold” and a consensus price target of GBX 2,021.30 ($26.59).
Shares of LON:REL opened at GBX 2,070 ($27.23) on Friday. The firm has a market cap of $39.44 billion and a PE ratio of 26.85. The firm’s fifty day moving average is GBX 1,989.27 and its 200-day moving average is GBX 1,906.62. The company has a debt-to-equity ratio of 308.02, a quick ratio of 0.40 and a current ratio of 0.45. Relx has a 52 week low of GBX 1,597 ($21.01) and a 52 week high of GBX 2,100 ($27.62).
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.